Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Clorprenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.97 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.97 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clorprenaline SCHEMBL406791 | 1.00 | ADRB2 (0.97) | ADRB2ADRB1BLMCYP2D6HIF1A | |
| Clorprenaline SCHEMBL2852861 | 0.98 | ADRB2 (0.93) | ADRB2ADRB1BLMCYP2D6HIF1A | |
| Clorprenaline SCHEMBL29417577 | 0.98 | ADRB2 (0.93) | ADRB2ADRB1BLMCYP2D6HIF1A | |
| Clorprenaline SCHEMBL15568417 | 0.98 | ADRB2 (0.93) | ADRB2ADRB1BLMCYP2D6HIF1A | |
| Clorprenaline SCHEMBL45370 | 0.98 | ADRB2 (0.93) | ADRB2ADRB1BLMCYP2D6HIF1A | |
| Clorprenaline SCHEMBL250611 | 0.98 | ADRB2 (1.00) | ADRB2ADRB1BLMCYP2D6HIF1A | |
| Clorprenaline SCHEMBL29483933 | 0.98 | ADRB2 (1.00) | ADRB2ADRB1BLMCYP2D6HIF1A | |
| Clorprenaline SCHEMBL2852860 | 0.97 | ADRB2 (0.90) | ADRB2ADRB1BLMCYP2D6HIF1A | |
| Clorprenaline SCHEMBL1650012 | 0.93 | ADRB2 (0.90) | ADRB2ADRB1BLMCYP2D6HIF1A | |
| Clorprenaline SCHEMBL122700 | 0.91 | ADRB2 (0.85) | ADRB2ADRB1BLMCYP2D6HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132115-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | TIANJIN GUDUI BIO PHARM CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-4600244-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS, AND USES | Tianjin Gudui Bio-Pharm Co., Ltd. (CN) | 2025-08-13 | — | — | EP | claimed |
| WO-2024078387-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS, AND USES | 天津谷堆生物医药科技有限公司 | 2024-04-18 | — | — | WO | claimed |
| US-20260144747-A1 | SYRUP PREPARATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-28 | — | — | US | disclosed |
| US-20260132115-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | TIANJIN GUDUI BIO PHARM CO LTD (CN) | 2026-05-14 | — | — | US | disclosed |
| EP-4600244-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS, AND USES | Tianjin Gudui Bio-Pharm Co., Ltd. (CN) | 2025-08-13 | — | — | EP | disclosed |
| US-12233071-B2 | Medicament for treating cough | NIPPON CHEMIPHAR CO., LTD. (JP) | 2025-02-25 | — | — | US | disclosed |
| EP-4424313-A1 | SYRUP PREPARATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024078387-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS, AND USES | 天津谷堆生物医药科技有限公司 | 2024-04-18 | — | — | WO | disclosed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20230248738-A1 | MEDICAMENT FOR TREATING COUGH | NIPPON CHEMIPHAR CO., LTD (JP) | 2023-08-10 | — | — | US | disclosed |
| US-11666582-B2 | Medicament for treating cough | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-06-06 | — | — | US | disclosed |
| WO-2023074785-A1 | SYRUP PREPARATION | 中外製薬株式会社 | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233071-B2 | Medicament for treating cough | P2RX4, P2RX3, P2RX5 | ADRB2 74/4885ADRB1 72/4885ADRB3 64/4885 |
| US-20260132115-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | BACE1, IL1B, CYP11B1 | ADRB2 548/4885ADRB1 222/4885ADRB3 291/4885 |
| US-11666582-B2 | Medicament for treating cough | P2RX4, P2RX3, P2RX5 | ADRB2 74/4885ADRB1 72/4885ADRB3 64/4885 |
| US-20260144747-A1 | SYRUP PREPARATION | ALK, IRAK1, IRAK3 | ADRB2 2541/4885ADRB1 1377/4885ADRB3 1260/4885 |
| US-20230248738-A1 | MEDICAMENT FOR TREATING COUGH | P2RX4, P2RX3, P2RX5 | ADRB2 74/4885ADRB1 72/4885ADRB3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.